Lundbeck preps for war against generic drugmakers in US

Lundbeck is facing a patent dispute concerning its second-best selling drug, schizophrenia treatment Rexulti, against companies wanting to reproduce generic versions. CEO Deborah Dunsire will sound the charge this summer.

Photo: Lundbeck / PR

Pharmaceutical firm Lundbeck is arming itself for battle with several generic drugmakers wanting to produce generic versions of schizophrenia treatment Rexulti before its patent expires.

Alongside Japanese partner Otsuka, Lundbeck is prepping for court, where the patent brawl is set to start on July 25, 2022.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs